HS-130

HS-130: The First Allogeneic, Off-the-Shelf Cell Therapy that Delivers Localized OX40-mediated Co-Stimulation to Enhance T-cell Activation in Lung Cancer (NSCLC)

HS-130 is designed to enhance the gp96 platform by facilitating antigen-driven T-cell activation and OX40L co-stimulation in a single product. The T-cell co-stimulatory fusion protein OX40L-Ig has the potential to combine with other immunotherapies, including HS-110, to potentially enhance the activation of antigen-specific CD8+ T-cells, stimulate the generation of long-lasting T-cell memory, and support the differentiation of T follicular helper cells that facilitate antibody production by B cells.

How it works

  • OX40L is a T cell co-stimulatory protein stably expressed on several antigen presenting cell (APC) types including dendritic cells and macrophages. 
  • The receptor OX40 is expressed on the surface of active T cells, NK cells, and neutrophils.
  • OX40-OX40L interaction promotes effector T-cell survival, induces memory T-cell generation, and can inhibit Treg differentiation and immune suppression.
  • HS-130 utilizes an immunoglobulin engineered version of OX40L-Ig to constitutively export the T cell co-stimulator.
  • OX40L-Ig interaction with OX40 on activated T cells has the potential to enhance the activation of antigen-specific CD8+ T-cells, stimulate the generation of long-lasting T-cell memory, and support the differentiation of T follicular helper cells that facilitate antibody production by B cells that all contribute to the anti-tumor response. 

HS-130 Phase 1 Clinical Trial in Solid Tumors

We have completed enrollment of our first-in-human Phase 1 open label dose-escalation study evaluating the safety of HS-130 in combination with HS-110 for the treatment of advanced solid tumors. The findings of this program are contributing to the development of the NightHawk RapidVax platform.
Clinical Trials RapidVax Technology